We also present a new CDC family health history feature: “Knowing is not Enough”.
Juan L. Rodriguez, MPH, MS; Cheryll C. Thomas, MSPH; Greta M. Massetti, PhD; et al.
MMWR Morb Mortal Wkly Rep 2016;65:1291–4
MMWR Morb Mortal Wkly Rep 2016;65:1305
CDC Grand Rounds: Family History and Genomics as Tools for Cancer Prevention and Control
- Moyer VA; U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160:271–81. PubMed
- Petrucelli N, Daly MB, Feldman GL. BRCA1 and BRCA2 hereditary breast and ovarian cancer. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2013. http://www.ncbi.nlm.nih.gov/books/NBK1247/
- Nelson HD, Fu R, Goddard K, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. Preventive Services Task Force recommendation evidence synthesis no. 101. Agency for Healthcare Research and Quality publication no. 12–05164-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
- Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117–30. CrossRef PubMed
- Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329–33. CrossRef PubMed
- Moyer VA; US Preventive Services Task Force. Medications for risk reduction of primary breast cancer in women: US Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:698–708. PubMed
- Kohlmann W, Gruber SB. Lynch syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews [Internet]. Seattle WA: University of Washington, Seattle; 2014. http://www.ncbi.nlm.nih.gov/books/NBK1211/
- Kaz AM, Brentnall TA. Genetic testing for colon cancer. Nat Clin Pract Gastroenterol Hepatol 2006;3:670–9. CrossRef PubMed
- Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:42–65. CrossRef PubMed
- Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35–41. CrossRef PubMed
- Trivers KF, Rodriguez JL, Cox SL, Crane BE, Duquette D. The activities and impact of state programs to address hereditary breast and ovarian cancer, 2011–2014. Healthcare (Basel) 2015;3:948–63. CrossRef PubMed
- Dotson WD, Douglas MP, Kolor K, et al. Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clin Pharmacol Ther 2014;95:394–402. CrossRefPubMed
- Khoury MJ, Bowen MS, Burke W, et al. Current priorities for public health practice in addressing the role of human genomics in improving population health. Am J Prev Med 2011;40:486–93.CrossRef PubMed
- Khoury MJ, Galea S. Will precision medicine improve population health? JAMA 2016;316:1357–8. CrossRef PubMed
- McCarthy AM, Bristol M, Domchek SM, et al. Health care segregation, physician recommendation, and racial disparities in BRCA1/2 testing among women with breast cancer. J Clin Oncol 2016;34:2610–8. CrossRef PubMed
TABLE 1. Estimated number of cancers diagnosed among the general population and among women with a BRCA mutation (breast and ovarian cancers) and among persons with Lynch syndrome (colorectal cancer)
|Type of Cancer||Women in general population||Women with BRCA mutation*|
|Colorectal cancer||Persons in general population||Persons with Lynch syndrome†|
Source: Michigan Department of Health and Human Services BRCA Clinical Genetic Counseling Database.
|Tier||Evidence for recommendation||Examples|
|Tier 1||Supported by a base of synthesized evidence for implementation practice||HBOC, Lynch syndrome, newborn screening|
|Tier 2||Synthesized evidence is insufficient to support routine implementation in practice; may provide information for informed decision making||Many pharmacogenomics tests|
|Tier 3||Evidence-based recommendation against use; or not relevant synthesized evidence identified; not ready for routine implementation in practice||Direct-to-consumer personal genetic tests|